The FMA lawyer said expanding on the pleadings in the way requested could be subject to "misuse" during the trial, which is due to begin in September.
Warminger, a portfolio manager at Milford Asset Management who has been on extended leave since last year, has denied the allegations against him.
Smith, during his submissions this morning, traversed one of the 10 causes of action in the FMA's case.
It involved trades in Fisher and Paykel Healthcare shares on May 27, 2014.
Warminger, according to Smith, had use of a direct market access facility through Macquarie Bank that let him buy shares.
On that particular morning in May, Warminger allegedly learned from contacts at Forsyth Barr and Goldman Sachs that they wanted to buy large parcels of F&P shares in off-market trades, Smith said.
The shares were trading publicly at $4.31 each, Smith said, and Warminger allegedly indicated to a trader who contacted him that he may sell for $4.35 a piece.
In the meantime, he used his direct market access for a series of smaller trades that increased the price of the technology company's shares.
Warminger then allegedly sold shares in off-market trades for $4.35 each.
Warminger's conduct was "unquestionably" market manipulation, Smith alleged.
Smith later said that there could be no need for further particulars from the FMA on the question of Warminger's knowledge.
"You assume he knew what he was doing when he was doing it," he said.
Justice Asher reserved his decision on the application.
The case against Warminger followed Milford paying $1.5 million as part of a settlement with the FMA after a market manipulation probe.
